NCT07192185招募中2 期
Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab: a Single Arm Trial.
Sun Yat-sen University1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2025年9月17日最近更新:
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- ORR via mRECIST
研究概览
简要总结
Atezolizumab plus bevacizumab is the first-line treatment for advanced hepatocellular carcinoma (HCC). However, the effect of the second-line treatment after the progress of Atezolizumab plus bevacizumab therapy remains unsatisfactory. This is a prospective trial to investigate the efficacy and safety of systemic chemotherapy with FOLFOX plus Atezolizumab & bevacizumab as second-line treatment for patients with advanced HCC who previously received atezolizumab plus bevacizumab
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The diagnosis of HCC was based on the diagnostic criteria for HCC used by the European Association for the Study of the Liver (EASL)
- •Patients must have at least one tumor lesion that can be accurately measured according to EASL criteria.
- •Barcelona clinic liver cancer-stage C
- •Patients who have previously received first-line treatment with atezolizumab plus bevacizumab and who have shown tumor progression as confirmed by imaging studies. No other systemic treatments have been administered.
- •Eastern Cooperative Oncology Group performance status of 0 to 2
- •No Cirrhosis or cirrhotic status of Child-Pugh class A only
- •Not amendable to surgical resection ,local ablative therapy and any other cured treatment.
- •The following laboratory parameters:
- •Hemoglobin ≥ 8.5 g/dL Total bilirubin ≤ 30mmol/L Serum albumin ≥ 30 g/L ASL and AST ≤ 5 x upper limit of normal Serum creatinine ≤ 1.5 x upper limit of normal INR ≤ 1.5 or PT/APTT within normal limits Absolute neutrophil count (ANC) >1,500/mm3
- •Ability to understand the protocol and to agree to and sign a written informed consent document
排除标准
- •Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy
- •Known history of HIV
- •History of organ allograft
- •Known or suspected allergy to the investigational agents or any agent given in association with this trial.
- •Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
- •Evidence of bleeding diathesis.
- •Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry.
- •Known central nervous system tumors including metastatic brain disease
研究组 & 干预措施
FOLFOX+TA
Experimental
Systemic chemotherapy with FOLFOX plus Atezolizumab & bevacizumab
干预措施: FOLFOX (Drug)
FOLFOX+TA
Experimental
Systemic chemotherapy with FOLFOX plus Atezolizumab & bevacizumab
干预措施: Atezolizumab & Bevacizumab (Drug)
结局指标
主要结局
ORR via mRECIST
时间窗: 12 months
CR+PR via mRECIST
次要结局
- OS(12 months)
- Progression Free Survival (PFS)(12 months)
- Adverse Events(12 months)
研究者
Shi Ming
Professor
Sun Yat-sen University
研究点 (1)
Loading locations...
相似试验
招募中
2 期
HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 TrialHepatocellular CarcinomaNCT05886465Sun Yat-sen University40
已完成
不适用
Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular CarcinomaHepatocellular CarcinomaNCT06199297Sun Yat-sen University188
终止
2 期
Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCCHepatocellular CarcinomaBCLC Stage B Hepatocellular CarcinomaNCT05776875Yale University3
招募中
2 期
FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver MetastasisNCT06988852Tongji Hospital300
已完成
不适用
Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCCAdvanced Hepatocellular CarcinomaNCT04862949CHA University131